CRNX
Crinetics Pharmaceuticals, Inc.
$34.47
+2.80%
$3.6B
No data for this timeframe.
Vol
Market Cap$3.6B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders50 funds
Inst. Value$3.0B
Inst. Activity11 buys / 6 sells
Insider Activity0B / 7S
Insider Net $-$4.9M
SEC Reports5
Press Releases2
Recent Activity
Jun 14, 2026
Press
Crinetics presented positive Phase 2 CAH data at ENDO 2026 showing atumelnant reduced androstenedione by 67% at week 12
Impact 6/10
Jun 14, 2026
fda
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
<p align="center"><em>Data show investigational atumelnant drove sustained androgen reductions while
Jun 14, 2026
Press
Crinetics presented two-year open-label extension data at ENDO 2026 showing that once-daily oral PALSONIFY (paltusotine)
Impact 6/10
May 29, 2026
Insider
Struthers Richard Scott gifted 222,200 shares
President & CEO
May 7, 2026
SEC
Crinetics reported Q1 2026 revenue of $10.7M (vs $0.4M YoY), driven by $10.3M in PALSONIFY net product revenue, nearly d
8-K — Impact 5/10
Apr 10, 2026
SEC
Crinetics Pharmaceuticals announced the departure of Jeff Knight as Chief Development and Operating Officer, effective A
8-K — Impact 3/10
Apr 8, 2026
SEC
Crinetics Pharmaceuticals announced a future earnings date for Q1 2026 but did not release actual financial results in t
PRESS-RELEASE — Impact 3/10
Apr 8, 2026
Insider
Knight Jeff E. acquired via exercise 49,474 shares
Chief Dev. & Operating Officer @ $23.98 ($1.2M)
Price Targets
$83.14
+141.2% upside
Strong Buy
Current $34.47
Low $55.00
Median $86.00
High $97.00
14 analysts
$55.00
$97.00
Analyst Ratings
7Strong Buy
13Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | Citizens | REITERATE | Market Outperform → Market Outperform |
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| May 11, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Apr 28, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.23 | $-1.35 — $-1.04 | -0% YoY | 10 |
| Next Q | $-1.22 | $-1.34 — $-0.95 | 12% YoY | 10 |
| Current FY | $-4.78 | $-5.25 — $-3.87 | 3% YoY | 11 |
| Next FY | $-4.21 | $-5.12 — $-3.38 | 12% YoY | 10 |
Latest Reports
BULLISH
Press
6/10
Crinetics presented positive Phase 2 CAH data at ENDO 2026 showing atumelnant reduced androstenedione by 67% at week 12
Jun 14, 2026
NEUTRAL
8-K
5/10
Crinetics reported Q1 2026 revenue of $10.7M (vs $0.4M YoY), driven by $10.3M in PALSONIFY net product revenue, nearly d
May 7, 2026
NEUTRAL
8-K
3/10
Crinetics Pharmaceuticals announced the departure of Jeff Knight as Chief Development and Operating Officer, effective A
Apr 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| FMR LLC | $572.4M | — |
| BlackRock, Inc. | $308.0M | — |
| FARALLON CAPITAL MANAGEMENT LLC | $302.8M | EXIT |
| WELLINGTON MANAGEMENT GROUP LLP | $296.3M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Struthers Richard | G | $0.00 |
| Apr 8, 2026 | Knight Jeff | M | $1.2M |
| Apr 8, 2026 | Knight Jeff | SELL | $3.4M |
| Mar 16, 2026 | Struthers Richard | SELL | $489.7K |
| Mar 16, 2026 | Knight Jeff | SELL | $220.8K |
50 institutional holders with $3.0B total value (83,122,055 shares) as of 2026-Q1. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 11 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | FMR LLC | 15,759,799 | $572.4M | 19.0% | — |
| 3 | BlackRock, Inc. | 8,478,815 | $308.0M | 10.2% | — |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 8,338,098 | $302.8M | 10.0% | EXIT -100.0% |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 8,157,204 | $296.3M | 9.8% | ADD +44.3% |
| 6 | DRIEHAUS CAPITAL MANAGEMENT LLC | 6,395,922 | $232.3M | 7.7% | — |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 4,673,935 | $169.8M | 5.6% | — |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,638,511 | $168.5M | 5.6% | — |
| 9 | JANUS HENDERSON GROUP PLC | 4,520,251 | $164.2M | 5.4% | — |
| 10 | STATE STREET CORP | 2,403,046 | $87.3M | 2.9% | TRIM -31.5% |
| 11 | BAKER BROS. ADVISORS LP | 2,351,465 | $85.4M | 2.8% | ADD +42.6% |
| 12 | Pictet Asset Management Holding SA | 1,884,281 | $68.2M | 2.3% | — |
| 13 | BNP Paribas Asset Management Holding S.A. | 1,716,445 | $62.3M | 2.1% | ADD +29.3% |
| 14 | RTW INVESTMENTS, LP | 1,451,326 | $52.7M | 1.7% | ADD +54.9% |
| 15 | MORGAN STANLEY | 919,686 | $33.4M | 1.1% | — |
| 16 | Hood River Capital Management LLC | 907,412 | $33.0M | 1.1% | — |
| 17 | JENNISON ASSOCIATES LLC | 904,672 | $32.9M | 1.1% | TRIM -29.4% |
| 18 | DIMENSIONAL FUND ADVISORS LP | 852,258 | $30.9M | 1.0% | ADD +55.2% |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 833,418 | $30.3M | 1.0% | — |
| 20 | AMERIPRISE FINANCIAL INC | 798,334 | $29.0M | 1.0% | ADD +32.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | ADD | 1,648,869 | 2,351,465 | +42.6% | $85.4M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 1,327,382 | 1,716,445 | +29.3% | $62.3M | 2026-Q1 |
| JENNISON ASSOCIATES LLC | TRIM | 1,281,601 | 904,672 | -29.4% | $32.9M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 548,977 | 852,258 | +55.2% | $30.9M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 601,190 | 798,334 | +32.8% | $29.0M | 2026-Q1 |
| MARSHALL WACE, LLP | NEW | — | 684,108 | — | $24.8M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | DOUBLED | 187,433 | 382,363 | +104.0% | $13.1M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 138,685 | 99,364 | -28.4% | $3.6M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 33,150 | 51,365 | +54.9% | $1.9M | 2026-Q1 |
| GLENMEDE TRUST CO NA | ADD | 16,944 | 29,245 | +72.6% | $1.1M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 5,615 | 15,310 | +172.7% | $556.1K | 2026-Q1 |
| Amundi | DOUBLED | 5,622 | 13,034 | +131.8% | $473.4K | 2026-Q1 |
| XPONANCE LLC | ADD | 7,195 | 9,043 | +25.7% | $328.4K | 2026-Q1 |
| Neuberger Berman Group LLC | NEAR_EXIT | 182,188 | 7,038 | -96.1% | $255.6K | 2026-Q1 |
| STRS OHIO | TRIM | 5,300 | 3,500 | -34.0% | $127.1K | 2026-Q1 |
| Point72 Asset Management, L.P. | EXIT | 2,337,034 | 0 | -100.0% | $0.00 | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | EXIT | 233,197 | 0 | -100.0% | $0.00 | 2026-Q1 |
| BAKER BROS. ADVISORS LP | DOUBLED | 280,000 | 1,648,869 | +488.9% | $76.8M | 2025-Q4 |
| RTW INVESTMENTS, LP | ADD | 872,387 | 1,351,326 | +54.9% | $62.9M | 2025-Q4 |
| JENNISON ASSOCIATES LLC | TRIM | 2,044,734 | 1,281,601 | -37.3% | $59.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 601,042 | 801,314 | +33.3% | $37.3M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 377,802 | 548,977 | +45.3% | $25.6M | 2025-Q4 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 34,694 | 302,001 | +770.5% | $14.1M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 14,045 | 233,197 | +1560.4% | $10.9M | 2025-Q4 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | DOUBLED | 87,318 | 187,433 | +114.7% | $8.9M | 2025-Q4 |
7 unique insiders with 19 transactions. Net insider value: -$4.9M ($0.00 bought, $4.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Struthers Richard Scott | President & CEO | GIFT | 222,200 | — | — |
| Apr 8, 2026 | Knight Jeff E. | Chief Dev. & Operating Officer | EXERCISE | 49,474 | $23.98 | $1.2M |
| Apr 8, 2026 | Knight Jeff E. | Chief Dev. & Operating Officer | SELL | 85,163 | $40.10 | $3.4M |
| Mar 16, 2026 | Struthers Richard Scott | President & CEO | SELL | 13,196 | $37.11 | $489.7K |
| Mar 16, 2026 | Knight Jeff E. | Chief Operating Officer | SELL | 5,950 | $37.11 | $220.8K |
| Mar 16, 2026 | Betz Stephen F. | Chief Scientific Officer | SELL | 6,371 | $37.11 | $236.4K |
| Mar 12, 2026 | Vivaldi Coelho Rogerio | Director | SELL | 4,477 | $36.08 | $161.5K |
| Mar 3, 2026 | Okey Stephanie | Director | SELL | 3,000 | $39.67 | $119.0K |
| Mar 3, 2026 | Schilke Tobin | Chief Financial Officer | SELL | 6,713 | $39.67 | $266.3K |
| Feb 23, 2026 | Struthers Richard Scott | President & CEO | AWARD | 228,000 | — | — |
| Feb 23, 2026 | Knight Jeff E. | Chief Operating Officer | AWARD | 34,000 | — | — |
| Feb 23, 2026 | Schilke Tobin | Chief Financial Officer | AWARD | 50,000 | — | — |
| Feb 23, 2026 | Knight Jeff E. | Chief Operating Officer | AWARD | 55,000 | — | — |
| Feb 23, 2026 | Betz Stephen F. | Chief Scientific Officer | AWARD | 30,000 | — | — |
| Feb 23, 2026 | Betz Stephen F. | Chief Scientific Officer | AWARD | 47,000 | — | — |
| Feb 23, 2026 | Kalofonos Isabel | Chief Commercial Officer | AWARD | 55,000 | — | — |
| Feb 23, 2026 | Schilke Tobin | Chief Financial Officer | AWARD | 32,000 | — | — |
| Feb 23, 2026 | Kalofonos Isabel | Chief Commercial Officer | AWARD | 34,000 | — | — |
| Feb 23, 2026 | Struthers Richard Scott | President & CEO | AWARD | 62,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 3 neutral. Avg impact: 4.8/10.
NEUTRAL
8-K
5/10
Crinetics reported Q1 2026 revenue of $10.7M (vs $0.4M YoY), driven by $10.3M in PALSONIFY net produ
May 7, 2026
NEUTRAL
8-K
3/10
Crinetics Pharmaceuticals announced the departure of Jeff Knight as Chief Development and Operating
Apr 10, 2026
NEUTRAL
PRESS-RELEASE
3/10
Crinetics Pharmaceuticals announced a future earnings date for Q1 2026 but did not release actual fi
Apr 8, 2026
BEARISH
CLUSTER
6/10
Two corporate insiders at Crinetics Pharmaceuticals sold shares in the past week, including CEO Rich
Mar 18, 2026
MIXED
8-K
7/10
Crinetics Pharmaceuticals reported its first commercial revenue from PALSONIFY, generating $5.4 mill
Feb 26, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 22 analysts: 7 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$83.14 mean target
+141.2% upside
Strong Buy (1.31)
$55.00 Low
$97.00 High
| Metric | Value |
|---|---|
| Current Price | $34.47 |
| Target Low | $55.00 |
| Target Mean | $83.14 |
| Target Median | $86.00 |
| Target High | $97.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (1.31) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.23 | $-1.35 | $-1.04 | -0.2% | +0.0% | 4↑ 5↓ | $0.0B | 1340.7% | 10 |
| Next Q 2026-09-30 |
$-1.22 | $-1.34 | $-0.95 | 11.5% | +0.0% | 6↑ 3↓ | $0.0B | 13210.5% | 10 |
| Current FY 2026-12-31 |
$-4.78 | $-5.25 | $-3.87 | 3.4% | -0.2% | 5↑ 4↓ | $0.1B | 790.7% | 11 |
| Next FY 2027-12-31 |
$-4.21 | $-5.12 | $-3.38 | 12.0% | -0.5% | 3↑ 5↓ | $0.2B | 152.4% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.233 | |
| 7d ago | $-1.233 | |
| 30d ago | $-1.233 | |
| 60d ago | $-1.225 | -0.008 |
| 90d ago | $-1.225 | -0.008 |
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| May 11, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 28, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 2, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Jan 12, 2026 | Goldman Sachs | UPGRADE | Neutral | Buy |
| Jan 8, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Jan 6, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Feb 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Jan 1, 2026 | 7 | 12 | 3 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 14, 2026
fda
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
<p align="center"><em>Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementati
Jun 14, 2026
fda
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
<p align="center"><em>Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower
Jun 2, 2026
other
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
<p align="center"><em>Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to f
Jun 2, 2026
other
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
<p align="center"><em>Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acrome
May 22, 2026
other
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
<p align="justify">SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=HszNnSVHGtY5I2lIFiuBz5C1ZClazId5u
May 13, 2026
short_volume
Short Volume: CRNX — 63.5% short (0.4M / 0.6M)
Short: 378,156 | Exempt: 0 | TRF Vol: 595,775 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: CRNX — 67.6% short (0.4M / 0.6M)
Short: 404,873 | Exempt: 0 | TRF Vol: 599,283 | Short Ratio: 67.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: CRNX — 79.0% short (0.4M / 0.6M)
Short: 447,610 | Exempt: 14,898 | TRF Vol: 566,434 | Short Ratio: 79.0% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: CRNX — 64.8% short (1.4M / 2.1M)
Short: 1,385,401 | Exempt: 12,263 | TRF Vol: 2,137,353 | Short Ratio: 64.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
CRNX Q1 2026 Earnings After Market Close — 2026-05-07
May 7, 2026
short_volume
Short Volume: CRNX — 86.2% short (0.7M / 0.8M)
Short: 664,684 | Exempt: 3,375 | TRF Vol: 770,711 | Short Ratio: 86.2% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: CRNX — 79.4% short (0.5M / 0.6M)
Short: 460,415 | Exempt: 6,986 | TRF Vol: 580,218 | Short Ratio: 79.4% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: CRNX — 81.1% short (1.0M / 1.3M)
Short: 1,047,323 | Exempt: 250 | TRF Vol: 1,291,086 | Short Ratio: 81.1% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: CRNX — 65.2% short (0.5M / 0.8M)
Short: 535,199 | Exempt: 0 | TRF Vol: 821,397 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
other
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
<p align="center"><em>PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union</em></p>
Mar 30, 2026
Clinical Trial
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Phase Phase 2 — COMPLETED